

TABLE E-1 Summary of Gait Improvement Assessed at Six Weeks, Three Months, Six Months, Twelve Months, and Twenty-four Months Postoperatively\*

	Prestige ST Trial†			Bryan Trial†		
	Disc Arthroplasty‡	Arthrodesis‡	P Value§	Disc Arthroplasty‡	Arthrodesis‡	P Value§
6 weeks			0.894			0.067
Improvement	22 (37.9%) [25.5% to 51.6%]	20 (39.2%) [25.8% to 53.9%]		21 (44.7%) [30.2% to 60.0%]	11 (26.8%) [14.2% to 42.9%]	
Maintenance	36 (62.1%) [48.4% to 74.5%]	31 (60.8%) [46.1% to 74.2%]		26 (55.3%) [40.1% to 69.8%]	29 (70.7%) [54.5% to 83.9%]	
Deterioration	0 (0.0%)	0 (0.0%)		0 (0.0%)	1 (2.4%) [0.06% to 12.9%]	
3 months			0.659			0.032
Improvement	18 (36.0%) [22.9% to 50.8%]	19 (40.4%) [26.4% to 55.7%]		22 (47.8%) [32.9% to 63.1%]	10 (27.0%) [13.8% to 44.1%]	
Maintenance	32 (64.0%) [49.2% to 77.1%]	28 (59.6%) [44.3% to 73.6%]		24 (52.2%) [37.0% to 67.1%]	25 (67.6%) [50.2% to 82.0%]	
Deterioration	0 (0.0%)	0 (0.0%)		0 (0.0%)	2 (5.4%) [0.7% to 18.2%]	
6 months			0.600			0.06
Improvement	20 (39.2%) [25.8% to 53.9%]	16 (34.0%) [20.9% to 49.3%]		22 (48.9%) [34.3% to 63.5%]	11 (30.6%) [15.5% to 45.6%]	
Maintenance	31 (60.8%) [46.1% to 74.2%]	31 (66.0%) [50.7% to 79.1%]		23 (51.1%) [36.5% to 65.7%]	23 (63.9%) [48.2% to 79.6%]	
Deterioration	0 (0.0%)	0 (0.0%)		0 (0.0%)	2 (5.6%) [−1.9% to 13.0%]	
12 months			0.439			0.043
Improvement	23 (41.1%) [28.1% to 55.0%]	14 (33.3%) [19.6% to 50.0%]		22 (48.9%) [33.7% to 64.2%]	9 (27.3%) [13.3% to 45.5%]	
Maintenance	33 (58.9%) [45.0% to 71.9%]	28 (66.7%) [50.5% to 80.4%]		23 (51.1%) [35.8% to 66.3%]	23 (69.7%) [51.3% to 84.4%]	
Deterioration	0 (0.0%)	0 (0.0%)		0 (0.0%)	1 (3.0%) [0.1% to 15.8%]	
24 months			0.358			0.102
Improvement	23 (47.9%)	14 (37.8%)		18 (46.2%)	8 (26.7%) [12.3%	

	[33.3% to 62.8%]	[22.5% to 55.2%]		[30.1% to 62.8%]	to 45.9%]	
Maintenance	25 (52.1%) [37.2% to 66.7%]	23 (62.2%) [44.8% to 77.5%]		21 (53.8%) [37.2% to 69.9%]	22 (73.3%) [54.1% to 87.7%]	
Deterioration	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	

\*Improvement was defined as postoperative improvement in the Nurick grade, maintenance was defined as no postoperative change in the Nurick grade, and deterioration was defined as postoperative decrease in the Nurick grade. †Both trials were Food and Drug Administration Investigational Device Exemption trials. ‡The values are given as the number of patients, with the percentage in parentheses and the 95% confidence interval in brackets. §P values are from the nonparametric Wilcoxon rank-sum test.